Progression of mild cognitive impairment to dementia due to AD in clinical settings
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: To describe the positive predictive value of mild cognitive impairment (MCI) and the factors associated with progression in routine practice.
Methods: A retrospective cohort study was conducted from the French National Alzheimer Database. Among 446,439 patients cared for in the participating centers between January 2009 and January 2014, 45,386 (10.2%) were classified as having MCI and 23,676 had at least one follow-up visit. Annual progression rate was used to describe the progression of patients with MCI to dementia due to Alzheimer disease. Hazard ratios of dementia due to Alzheimer disease were estimated using Cox regression model.
Results: Annual progression rate (95% confidence interval) was 13.7% person-years (py) (13.5%–13.9%) with higher rate for amnestic MCI (aMCI) (18.2% py [17.9%–18.5%]) than for nonamnestic MCI (naMCI) (9.5% py [9.3%–9.6%]). Separate regression models were performed for each MCI subtype. Higher education, older age, female sex, and lower Mini-Mental State Examination score were associated with an increased risk of progression for both subtypes. Use of anxiolytics (adjusted hazard ratio [95% confidence interval]: 0.77 [0.66–0.91]) was a protective factor for aMCI whereas antidepressant drugs (1.16 [1.04–1.29]) were associated with an increased risk. For naMCI, prescriptions of antidepressants (0.85 [0.74–0.98]) and antipsychotics (0.55 [0.32–0.93]) were protective for progression.
Conclusions: Under circumstances emulating routine clinical practice, the positive predictive value of an MCI diagnosis is in line with previous clinical studies and the external validity of the concept is strengthened. Distinguishing between aMCI and naMCI is particularly relevant.
GLOSSARY
- AD=
- Alzheimer disease;
- aMCI=
- amnestic mild cognitive impairment;
- APR=
- annual progression rate;
- BNA=
- Banque Nationale Alzheimer;
- CI=
- confidence interval;
- CMRR=
- center of memory resources and research;
- HR=
- hazard ratio;
- ICD-10=
- International Classification of Diseases, Tenth Revision;
- MC=
- memory center;
- MCI=
- mild cognitive impairment;
- MMSE=
- Mini-Mental State Examination;
- naMCI=
- nonamnestic mild cognitive impairment;
- py=
- person-years
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received December 13, 2014.
- Accepted in final form March 26, 2015.
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Farwa Ali and Dr. Lauren Jackson
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodiesTanis J. Ferman, Glenn E. Smith, Kejal Kantarci et al.Neurology, November 08, 2013 -
Articles
Injury markers predict time to dementia in subjects with MCI and amyloid pathologyIneke A. van Rossum, Stephanie J.B. Vos, Leah Burns et al.Neurology, September 26, 2012 -
Articles
Mild cognitive impairmentLong-term course of four clinical subtypesA. Busse, A. Hensel, U. Gühne et al.Neurology, December 26, 2006 -
Article
Patterns of longitudinal cortical atrophy over 3 years in empirically derived MCI subtypesEmily C. Edmonds, Alexandra J. Weigand, Sean N. Hatton et al.Neurology, May 11, 2020